Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

相似書籍

• Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
  由: Bowyer, S, et al.
  出版: (2016)
• Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
  由: Prithviraj, Prashanth, et al.
  出版: (2015)
• Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
  由: Lipson, Evan J., et al.
  出版: (2011)
• Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy
  由: Parakh, Sagun, et al.
  出版: (2018)
• Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
  由: Karimi, Amirali, et al.
  出版: (2021)